Development pipeline
Advancing novel oral therapeutics through the reformulation of well-characterized molecules, starting with Horeb-101, to overcome historical bioavailability limitations
Strategic development approach
Our pipeline strategy focuses on advancing novel oral formulations that overcome traditional bioavailability barriers. By targeting multiple indications with shared mechanistic pathways, we maximize the therapeutic potential of each compound while maintaining development efficiency.
Horeb-101 is a novel oral formulation of niclosamide engineered to enhance solubility, stability and systemic exposure
3
>87%
Improved bioavailability
Target indications